Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.
The 21 amino acid signaling peptide endothelin-1 is commonly elevated in epithelial ovarian cancer, and it mediates or facilitates much of this cancer's aggressive behavior. Ambrisentan (Letairis; Gilead Sciences Inc.) is an antagonist of endothelin-1 at its cognate receptor that has just been approved to treat pulmonary hypertension. Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery.
Kast
R E
RE
Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com
D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D008969:Molecular Sequence Data; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D010666:Phenylpropionates / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019332:Endothelin-1; D010666:Phenylpropionates; D011724:Pyridazines; C467894:ambrisentan